TRIM63/IRF-8 axis promotes tumor progression and immunosuppression of melanoma with BRAF mutation

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The E3 ligase TRIM63 is linked to melanoma malignancy, especially in BRAF-mutated cases.
• BRAF mutations, like V600E, are common in melanoma, but the oncogenic mechanisms are unclear.

Purpose of the Study:

• To elucidate the mechanism by which TRIM63 contributes to melanoma progression, particularly in the context of BRAF mutations.
• To investigate the role of TRIM63 phosphorylation and its downstream targets in melanoma pathogenesis.

Main Methods:

• Assessed TRIM63 expression in melanoma cells.
• Investigated the effect of MAPK pathway activation on TRIM63.
• Analyzed TRIM63 phosphorylation at S69 and its interaction with IRF-8 using biochemical assays.
• Determined the ubiquitination and degradation of IRF-8 mediated by TRIM63.
• Correlated clinical data, including pS69 TRIM63 levels, with patient prognosis and immune status.

Main Results:

• TRIM63 is overexpressed in melanoma and its oncogenic activity is dependent on MAPK pathway activation.
• BRAF mutation triggers ERK1/2-mediated phosphorylation of TRIM63 at S69.
• Phosphorylated TRIM63 (pS69) binds to IRF-8, leading to its ubiquitination and degradation at K250.
• IRF-8 degradation by TRIM63 enhances tumor progression.
• Elevated pS69 TRIM63 levels correlate with tumor immunosuppression and poor patient prognosis.

Conclusions:

• TRIM63 plays a significant oncogenic role in melanoma by facilitating IRF-8 degradation through a BRAF-MAPK-ERK1/2-dependent pathway.
• Phosphorylated TRIM63 (pS69) is a key mediator of tumor progression and immune evasion in melanoma.
• TRIM63, particularly its phosphorylated form, represents a potential therapeutic target for melanoma treatment.